BiotechTube

5-fu + Lobaplatin + Placebo + leucogen

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasopharyngeal Carcinoma

Conditions

Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression

Trial Timeline

Apr 1, 2023 → Dec 1, 2029

NCT ID
NCT05780294

About 5-fu + Lobaplatin + Placebo + leucogen

5-fu + Lobaplatin + Placebo + leucogen is a phase 3 stage product being developed by Sun Pharmaceutical for Nasopharyngeal Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05780294. Target conditions include Nasopharyngeal Carcinoma, Leucogen, Chemotherapy.

What happened to similar drugs?

0 of 12 similar drugs in Nasopharyngeal Carcinoma were approved

Approved (0) Terminated (0) Active (12)
🔄CisplatinSun PharmaceuticalPhase 3
🔄Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
🔄CapecitabineSun PharmaceuticalPhase 3
🔄Nedaplatin + CisplatinSun PharmaceuticalPhase 3
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
🔄QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3
🔄docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05780294Phase 3Recruiting

Competing Products

20 competing products in Nasopharyngeal Carcinoma

See all competitors
ProductCompanyStageHype Score
Nanatinostat + Valganciclovir + PembrolizumabViracta TherapeuticsPhase 1
11
Cisplatin 2 + Docetaxel + Cisplatin 1Sun PharmaceuticalPhase 2
31
CisplatinSun PharmaceuticalPhase 3
36
Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
36
CapecitabineSun PharmaceuticalPhase 3
36
Amifostine every-other-day regimen + Amifostine everyday regimenSun PharmaceuticalPhase 2
31
Nedaplatin + CisplatinSun PharmaceuticalPhase 3
40
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
47
QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3
47
The combination treatment of anlotinib, penpulimab and capecitabine.Sun PharmaceuticalPhase 2
39
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3
47
Pemetrexed (Alimta)Eli LillyPhase 2
35
Camrelizumab + Placebos + Gemcitabine + CisplatinJiangsu Hengrui MedicinePhase 3
36
Famitinib + CisplatinJiangsu Hengrui MedicinePhase 1
29
SHR-1210 + Gemcitabine + cis-platinumJiangsu Hengrui MedicinePhase 1
29
SHR-1701 + Gemcitabine + Cisplatin + Albumin PaclitaxelJiangsu Hengrui MedicinePhase 1
25
FamitinibJiangsu Hengrui MedicinePhase 2
35
ApatinibJiangsu Hengrui MedicinePhase 2
35
SHR-1210Jiangsu Hengrui MedicinePhase 2
35
SHR-1701 + FamitinibJiangsu Hengrui MedicinePhase 1/2
28